Gradalis® Announces Initiation of Phase 3 Study of Vigil™ in Ewing’s sarcoma
August 28, 2018 19:16 ET
|
Gradalis, Inc.
– The open-label trial will measure progression free survival of participants from date of randomization until first disease progression in the study – – The trial will use product produced from...
Gradalis, Inc. Appoints Sunil Joshi Chief Executive Officer
May 04, 2016 08:30 ET
|
Gradalis, Inc.
DALLAS, May 04, 2016 (GLOBE NEWSWIRE) -- Gradalis, Inc. today announced the appointment of Sunil Joshi as Chief Executive Officer. Mr. Joshi is a highly experienced Pharma/Biotech business...
Gradalis, Inc. Announces Initiation of a Phase 2 Study using Gradalis’ Vigil® Immunotherapy in Combination with Anti-PD-1 Technology to Treat Patients with Advanced Non-Small Cell Lung Cancer
April 26, 2016 09:15 ET
|
Gradalis, Inc.
DALLAS, April 26, 2016 (GLOBE NEWSWIRE) -- Gradalis Inc., a clinical-stage biopharmaceutical company, today announced the initiation of a Phase 2 study for the treatment of patients with advanced...
Gradalis, Inc. Announces Initiation of a Phase 2b Study of Vigil(TM) Cancer Vaccine in Ewing’s Sarcoma
July 09, 2015 09:15 ET
|
Gradalis, Inc.
DALLAS, July 09, 2015 (GLOBE NEWSWIRE) -- Gradalis, Inc., a clinical-stage biopharmaceutical company, today announced the initiation of a Phase 2b study for its proprietary, personalized cancer...
Gradalis, Inc. Announces Presentation of Data From a Pilot Study of Vigil (TM) Cancer Vaccine in Ewing’s Sarcoma
June 04, 2015 09:15 ET
|
Gradalis, Inc.
DALLAS, June 04, 2015 (GLOBE NEWSWIRE) -- Gradalis Inc., a clinical-stage biopharmaceutical company, today announced that data from a pilot study for its proprietary personalized cancer vaccine,...
Gradalis, Inc. Announces Presentation of Phase 2 Data of Ovarian Cancer Patients Treated With Vigil(TM)
April 13, 2015 14:51 ET
|
Gradalis, Inc.
DALLAS, April 13, 2015 (GLOBE NEWSWIRE) -- Gradalis Inc., a late-stage biopharmaceutical company, today announced that Phase 2 data for its proprietary personalized immunotherapy, Vigil™ (previously...
Gradalis, Inc. Announces Initiation of a Phase 3 Registration Study for Vigil(TM) in Ovarian Cancer
February 26, 2015 11:36 ET
|
Gradalis, Inc.
DALLAS, Feb. 26, 2015 (GLOBE NEWSWIRE) -- Gradalis Inc., a late-stage biopharmaceutical company, today announced that it has initiated a Phase 3 registration trial for its proprietary autologous...
Gradalis, Inc. Announces Presentation of New Data
June 18, 2014 09:30 ET
|
Gradalis, Inc.
DALLAS, June 18, 2014 (GLOBE NEWSWIRE) -- Gradalis Inc., a late-stage oncology therapeutic company, today announced that new data from its lead cancer programs focused on its personalized...
Gradalis, Inc. Announces Dr. Scott Gottlieb Joins Board of Directors
June 04, 2014 09:15 ET
|
Gradalis, Inc.
DALLAS, June 4, 2014 (GLOBE NEWSWIRE) -- Gradalis Inc., a late stage clinical company, today announced that Scott Gottlieb, MD has joined its board of directors. Dr Gottlieb, MD is a practicing...